Utama › Glioblastoma › New York
Kajian klinikal Glioblastoma di New York
33 kajian untuk Glioblastoma sedang mencari peserta di lokasi di New York.
Bandar di New York
Teks kajian rasmi (Bahasa Inggeris)
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
- New York University Langone's Perlmutter Cancer Institute, New York
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06991101Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05432804A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center*, New York
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT03970447Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Weill Cornell Medicine, New York
- NewYork-Presbyterian / Columbia University Irving Medical Center, New York
- Lennox Hill Hospital, New York
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT05902169Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Northwell Health Center for Advanced Medicine - Brain Tumor Center, Lake Success
- Columbia University Irving Medical Center, New York
- Montefiore Medical Center, The Bronx
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07326566A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
- Lenox Hill Hospital, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05303467Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- Westchester Medical Center, Valhalla
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07195591A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT05765812ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
- Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT07089641Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center-Weiler Hospital, The Bronx
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT07452458A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Icahn School of Medicine at Mount Sinai - Oncology, New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus, New York
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT06914128Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- dan 1 lagi
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06934889Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT05303519INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT02977780A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
- NYU Langone Health, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT07464925Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- NYU Langone Health, New York
Mengambil peserta
Umur 18 hingga 85 · Semua jantina · Dikemas kini 21 Jul 2026 · NCT06910306Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
- Albany Medical Center, Albany
- Dent Neurologic Institute, Buffalo
- Northwell Health, Long Island City
- dan 4 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 17 Jul 2026 · NCT07225621DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- Lenox Hill Hospital, New York
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jul 2026 · NCT06805305A Study of 177Lu-PSMA-617 in People With Gliomas
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- dan 1 lagi
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT07223034Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
- Lenox Hill Brain Tumor Center, New York
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jun 2026 · NCT05954858Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- Lenox Hill Brain Tumor Center, New York
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jun 2026 · NCT05271240Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- Lenox Hill Brain Tumor Center, New York
Mengambil pesertaFasa 1/2
Umur 18 hingga 74 · Semua jantina · Dikemas kini 1 Jun 2026 · NCT03213002Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- Lenox Hill Brain Tumor Center, New York
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jun 2026 · NCT01269853Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
- Lenox Hill Brain Tumor Center, New York
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jun 2026 · NCT05979064Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- Lenox Hill Brain Tumor Center, New York
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jun 2026 · NCT02861898Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06810544Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- Lenox Hill Brain Tumor Center, New York
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT02800486Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Feb 2026 · NCT06058988Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
- Stony Brook University Hospital, Stony Brook
Mengambil pesertaFasa awal 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Dis 2025 · NCT05423210SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Buffalo
- Massive Bio SYNERGY-AI site, Hempstead
- Massive Bio SYNERGY-AI site, Manhasset
- dan 2 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- Columbia University Medical Center - Herbert Irving Pavilion, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Jun 2025 · NCT05879367Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- Northshore University Hospital, Manhasset
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Mac 2025 · NCT01906385Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.